Estudo citogenético, regiões 2q37e 22q13.3 e condições médicas em doenças do espectro autístico

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Imunomarcação de COX-2, PGE-2, VEGF e CASPASE-3 em mastocitomas cutâneos caninos

Pós-graduação em Medicina Veterinária - FMVZ

Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children

In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI) 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6%) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.

Luminescência e propriedades estruturais de 'LI''TA'O IND.3'nanoestruturado dopado com európio (III) e magnésio

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Synthesis, characterization, thermal behavior, and DFT calculation of solid 1,4-bis(3-carboxy-3-oxo-prop-1-enyl) benzene of some trivalent lanthanides

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Expressão de Pentraxina 3 em membranas corioamnióticas de gestações prétermo complicadas por rotura prematura de membranas pré-termo ou trabalho de parto prematuro

Pentraxina 3 (PTX3) é um componente essencial da resposta imune inata e age como receptores de reconhecimento de padrões (PPRs) reconhecendo produtos microbianos, opsonizando fungos, bactérias Gram positivas e negativas, além de apresentar a capacidade de ativar o sistema complemento. Poucos estudos na literatura mundial têm investigado a expressão de PTX3 nas complicações gestacionais associadas à invasão microbiana da cavidade amniótica e resultados conflitantes têm sido descritos. Avaliar a expressão gênica e protéica de PTX3 em membranas corioamnióticas de gestações pré-termo complicadas por Trabalho de Parto Prematuro (TPP) e bolsa íntegra ou Rotura Prematura de Membranas Pré-Termo (RPM-PT), na presença de corioamnionite histológica (CA). Foram incluídas no estudo 30 gestantes com TPP, sendo 15 na ausência e 15 na presença de corioamnionite histológica e 30 gestantes com RPM-PT, sendo 15 na ausência e 15 na presença de corioamnionite histológica. Cortes parafinizados foram encaminhados à análise histopatológica para confirmação de corioamnionite histológica. Outros fragmentos de 1cm2 das membranas foram submetidos à extração de RNA total. Após a extração do RNA, as amostras com concentração entre 0,02 e 0,2g/ L de RNA foram submetidas à obtenção de cDNA para posterior utilização na quantificação da expressão gênica de PTX3 pela técnica da PCR em tempo real empregando-se o Sistema TaqMan® Gene Expression Assays. Fragmentos das mesmas amostras incluídas no estudo foram utilizados para verificar a expressão da proteína PTX-3 através da técnica de Western Blotting. Dentre as 60 membranas corioamnióticas incluídas no estudo, 56 (93,3%) expressaram PTX-3. Não houve diferença estatisticamente significativa na expressão de mRNA de PTX-3 (p=0,137) entre os grupos: RPM-PT na presença de CA (Md: 0.355; 0.11-1.03), RPM-PT na...(Resumo completo, clicar acesso eletrônico abaixo)

Efeito do 1,3/1,6 beta-glucano no sistema imune de cadelas submetidas a ovário-histerectomia

Pós-graduação em Medicina Veterinária - FCAV

Toxicologia reprodutiva de ratos adultos expostos ao 2,3,7,8-Tetraclorodibenzo-P-Dioxina (TCDD) in útero

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Estudos sobre a aplicação do pentacloreto de nióbio na síntese de derivados de 4-aril-3,4-di- hidrocumarinas

Coumarin is a natural active compound that can be found in many plants. The coumarins have many properties such as bronchodilator, anti-inflammatory, antioxidant, anticoagulant, antibiotics, immunomodulatory, antimicrobial and antiviral, thus, they are widely used in medical applications. More recently the coumarin derivatives have attracted the interest of many research groups in the field of new materials, for example the possibility of their use as sensitizers in dye-sensitized solar cells (DSSC) and lasers. The MCRs are defined as a process in which three or more reactants are combined in the same reaction pot, resulting in products with good structural complexity a single step, in addition to economy of atoms and selectivity and is a very important feature in modern synthetic methodology. In this work we investigated the use of niobium pentachloride as catalyst of the multicomponent reactions between phenolic derivatives, various aromatic aldehydes and β-diester derivatives in the synthesis of 4-aryl-3,4-dihydrocoumarin derivatives. The reactions were carried out at room temperature, under inert atmosphere (N2), using dichloromethane anhydrous (CH2 Cl2) as solvent, with a reaction time of most 120 hours. The products were isolated by column chromatography on silica gel and submitted to spectrometric and spectroscopic analysis. The results show that NbCl5 is an excellent agent for promoting the synthesis of 4-aryl-3,4-dihydrocoumarin derivatives through multicomponent reactions, obtaining yields varying from 45 to 95%

Preanesthetic assessment data do not influence the time for tracheal intubation with Airtraq (TM) video laryngoscope in obese patients

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Obtenção e caracterização óptica e elétrica de 'La''Ta'O IND.4' e LiTaO Ind.3 puros e dopados com Eu POT.3+

Eletronicalceramics are used in many applications such as: multilayer capacitor, transducer, pyroelectric sensors and electrooptic devices. In recent years there has been a growing demand for eletronicalceramics with better performance and functionality. This demand has accelerated the development of synthesis techniques to produce powders with well-defined particle size, shape and crystallinity. The eletronicalceramics in the form of bulk are determined by their performance characteristics of the powders used and the preparation process. So, physical and chemical properties of powders, such as chemical control of stoichiometry, purity, homogeneity, particle size and shape should be observed when choosing the methods of synthesis. Among the techniques used so far, the polymeric precursor method, also known as Pechini, has been considered ideal for the preparation of nanosized powders. Thus, this research project aims to use the polymeric precursor method to prepare powders of lithium tantalate and lanthanum tantalate, with good chemical stability. In this aspect is proposed to investigate the effects of variation of the concentration of europium about the properties of tantalate because doping with Eu3 + indicates that they may occupy different sites in the crystal structure, as in the case of LiTaO3. Effects of things like occupation sites, stability of phases and formation temperature have been previously investigated by the group, which motivated the formulation of this project. Our proposal aims to introduce the Eu3 + LaTaO4 and LiTaO3 and study the structural and optical properties of the powders obtained by Pechini method, as well as correlate these studies with the electrical properties of the material, mainly the Ironelectricty Hysteresis.

Diferentes doses de Triiodotironina (T3) aumentam a expressão gênica de leptina, adiponectina e TRα com o envolvimento da via fosfatidil inositol 3 quinase (PI3K) em adipócitos, 3T3-L1

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Beta-alanine (Carnosyn (TM)) supplementation in elderly subjects (60-80 years): effects on muscle carnosine content and physical capacity

The aim of this study was to investigate the effects of beta-alanine supplementation on exercise capacity and the muscle carnosine content in elderly subjects. Eighteen healthy elderly subjects (60-80 years, 10 female and 4 male) were randomly assigned to receive either beta-alanine (BA, n = 12) or placebo (PL, n = 6) for 12 weeks. The BA group received 3.2 g of beta-alanine per day (2 x 800 mg sustained-release Carnosyn (TM) tablets, given 2 times per day). The PL group received 2 x (2 x 800 mg) of a matched placebo. At baseline (PRE) and after 12 weeks (POST-12) of supplementation, assessments were made of the muscle carnosine content, anaerobic exercise capacity, muscle function, quality of life, physical activity and food intake. A significant increase in the muscle carnosine content of the gastrocnemius muscle was shown in the BA group (+85.4%) when compared with the PL group (+7.2%) (p = 0.004; ES: 1.21). The time-to-exhaustion in the constant-load submaximal test (i.e., TLIM) was significantly improved (p = 0.05; ES: 1.71) in the BA group (+36.5%) versus the PL group (+8.6%). Similarly, time-to-exhaustion in the incremental test was also significantly increased (p = 0.04; ES 1.03) following beta-alanine supplementation (+12.2%) when compared with placebo (+0.1%). Significant positive correlations were also shown between the relative change in the muscle carnosine content and the relative change in the time-to-exhaustion in the TLIM test (r = 0.62; p = 0.01) and in the incremental test (r = 0.48; p = 0.02). In summary, the current data indicate for the first time, that beta-alanine supplementation is effective in increasing the muscle carnosine content in healthy elderly subjects, with subsequent improvement in their exercise capacity.

Effect of Nintendo Wii (TM)-based motor and cognitive training on activities of daily living in patients with Parkinson's disease: A randomised clinical trial

Objectives To investigate the effect of Nintendo Wii (TM)-based motor cognitive training versus balance exercise therapy on activities of daily living in patients with Parkinson's disease. Design Parallel, prospective, single-blind, randomised clinical trial. Setting Brazilian Parkinson Association. Participants Thirty-two patients with Parkinson's disease (Hoehn and Yahr stages 1 and 2). Interventions Fourteen training sessions consisting of 30 minutes of stretching, strengthening and axial mobility exercises, plus 30 minutes of balance training. The control group performed balance exercises without feedback or cognitive stimulation, and the experimental group performed 10 Wii Fit (TM) games. Main outcome measure Section II of the Unified Parkinson's Disease Rating Scale (UPDRS-II). Randomisation Participants were randomised into a control group (n = 16) and an experimental group (n = 16) through blinded drawing of names. Statistical analysis Repeated-measures analysis of variance (RM-ANOVA). Results Both groups showed improvement in the UPDRS-II with assessment effect (RM-ANOVA P < 0.001, observed power = 0.999). There was no difference between the control group and the experimental group before training {8.9 [standard deviation (SD) 2.9] vs 10.1 (SD 3.8)}, after training [7.6 (SD 2.9) vs 8.1 (SD 3.5)] or 60 days after training [8.1 (SD 3.2) vs 8.3 (SD 3.6)]. The mean difference of the whole group between before training and after training was -0.9 (SD 2.3, 95% confidence interval -1.7 to -0.6). Conclusion Patients with Parkinson's disease showed improved performance in activities of daily living after 14 sessions of balance training, with no additional advantages associated with the Wii-based motor and cognitive training. Registered on http://www.clinicaltrials.gov (identifier: NCT01580787). (C) 2012 Chartered Society of Physiotherapy. Published by Elsevier Ltd. All rights reserved.

Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous (TM) Bio-engineered R stent (TM): a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry

The National Institute for Clinical Excellence (NICE) guidelines recommend the use of bare-metal stents (BMS) in non-complex lesions with a low risk of restenosis (diameter a parts per thousand yen3 mm and lesion length a parts per thousand currency sign15 mm) and the use of drug-eluting stents (DES) in more complex lesions with a high risk of restenosis (diameter < 3.0 mm or lesion length > 15 mm). However, the guidelines were created based on studies evaluating BMS and DES only. We performed an analysis of patients undergoing non-urgent percutaneous coronary intervention with the novel endothelial cell capturing stent (ECS). The ECS is coated with CD34(+) antibodies that attract circulating endothelial progenitor cells to the stent surface, thereby accelerating the endothelialization of the stented area. We analyzed all patients enrolled in the worldwide e-HEALING registry that met the NICE criteria for either low-risk or high-risk lesions and were treated with a parts per thousand yen1 ECS. The main study outcome was target vessel failure (TVF) at 12-month follow-up, defined as the composite of cardiac death or MI and target vessel revascularization (TVR). A total of 4,241 patients were assessed in the current analysis. At 12-month follow-up, TVF occurred in 7.0% of the patients with low-risk lesions and in 8.8% of the patients with high-risk lesions (p = 0.045). When evaluating the diabetic patients versus the non-diabetic patients per risk group, no significant differences were found in TVF, MI or TVR in either risk group. The ECS shows good clinical outcomes in lesions carrying either a high or a low risk of restenosis according to the NICE guidelines with comparable rates of cardiac death, myocardial infarction, and stent thrombosis. The TVF rate with ECS was slightly higher in patients with high-risk lesions, driven by higher clinically driven TLR. The risk of restenosis with ECS in patients carrying high-risk lesions needs to be carefully considered relative to other risks associated with DES. Furthermore, the presence of diabetes mellitus did not influence the incidence of TVF in either risk group.